# Moderna and Merck personalized mRNA cancer vaccine cuts melanoma recurrence and death by 42 percent

Top-line Phase 3 results from 1,137 patients reveal individual tumor-tailored mRNA neoantigen therapy combined with Keytruda significantly improves survival ahead of FDA regulatory review.

- Canonical: https://reviewblip.com/news/moderna-and-merck-personalized-mrna-cancer-vaccine-cuts-melanoma-recurrence-and-death-by-42-percent/
- Published: 2026-10-24T00:04:58.664Z
- Updated: 2026-10-24T00:04:58.664Z
- Author: ReviewBlip
- Category: Useful AI & Computational Medicine
- Type: News

![Medical laboratory researcher holding cryogenic vial of personalized mRNA vaccine candidate](https://reviewblip.com/editorial-images/550506f9fccc9565c99d33098cbab2c3d570d03c71fa33bb69357a63eaa6b678)

Image credit: Getty Images / Nikolas Kokovlis — clinical oncology research editorial photo; distributed via Ars Technica

In a milestone moment for computational biotechnology and individualized medicine, pharmaceutical partners Merck & Co. and Moderna Inc. announced comprehensive Phase 3 clinical trial results demonstrating that a personalized mRNA cancer vaccine combined with standard immunotherapy reduced the risk of death or cancer recurrence by 42 percent in high-risk melanoma patients.

The pivotal trial, which enrolled 1,137 patients with resected stage IIB through IV cutaneous melanoma across international medical centers, evaluated the combination of Moderna's investigational individualized neoantigen therapy (designated mRNA-4157 / V940) alongside Merck's standard-of-care anti-PD-1 checkpoint inhibitor Keytruda (pembrolizumab), compared against Keytruda monotherapy alone. Over a multi-year tracking horizon, patients receiving the personalized mRNA regimen exhibited a statistically significant 42 percent reduction in recurrence-free survival events compared to those receiving standard immunotherapy.

The scientific architecture of mRNA-4157 represents a departure from traditional one-size-fits-all oncology drugs. Following surgical tumor resection, each patient's tumor biopsy and healthy tissue undergo high-depth genomic sequencing. Proprietary AI algorithms analyze the genetic discrepancies to predict up to 34 patient-specific neoantigens—mutated proteins unique to that individual's cancer cells that are most likely to trigger a robust immune attack. A custom mRNA sequence encoding these precise 34 neoantigens is synthesized, encapsulated in lipid nanoparticles, and administered to the patient, effectively training their T-cells to identify and eradicate any microscopic lingering tumor cells.

Originally embargoed ahead of a formal scientific presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid, the companies released top-line metrics early following an uncoordinated publication breach by an oncology industry outlet. Moderna and Merck confirmed that the complete peer-reviewed dataset has been accepted for imminent publication in the New England Journal of Medicine, with formal regulatory submissions to the U.S. Food and Drug Administration and the European Medicines Agency planned before the end of the quarter.

Our take: The 42 percent risk reduction in Phase 3 proves that mRNA is fundamentally an algorithmic platform for personalized medicine, not merely a pandemic vaccine delivery vehicle. Automated neoantigen prediction and rapid custom mRNA synthesis will define the next two decades of oncology.

## Sources
- [\[5\] Merck and Moderna Joint Phase 3 Clinical Readout for Personalized Melanoma Vaccine](https://arstechnica.com/health/2026/10/personalized-mrna-cancer-vaccine-cut-melanoma-death-recurrence-by-42/)